Pneumococcal vaccine for children: An updateelectroencephalographymonitoring[No authors listed]doi:10.1016/S0278-2316(83)80023-1Vincent A. FulginitiElsevier B.V.Infectious Diseases Newsletter
PCV15 and PCV20 are safe for children under 5, with doses given at2 months, 4 months, 6 months, and 12-15 months. Infants and very young children are at higher risk for several dangerous infections, includingpneumoniaandbacterial meningitis. Pneumococcal vaccine for children Children over 5 ...
1092 ANTIBODY RESPONSE TO PNEUMOCOCCAL VACCINE IN MALNOURISHED CHILDRENPediatric Research publishes original papers, invited reviews, and commentaries on the etiologies of diseases of children and disorders of development, extending from molecular biology to epidemiology. Use of model organisms and in vitro...
which also are the most frequently responsible for childhood pneumococcal infections in the developed world.[3,4]Numerous studies have shown that pneumococcal conjugate vaccines (PCVs) reduce the nasopharyngeal carriage of vaccine serotypes.[3,5,6,7,8,9]PCVs may then reduce the prevalence of ...
Pediatric Research publishes original papers, invited reviews, and commentaries on the etiologies of diseases of children and disorders of development, extending from molecular biology to epidemiology. Use of model organisms and in vitro techniques relevant to developmental biology and medicine are ...
(keeping in the control group the 23 percent of controls who received pneumococcal conjugate vaccine after the completion of the trial). A total of 359 children were hospitalized for asthma, and 1210 were seen in the emergency department for asthma. The risk of asthma that required ...
Infants, children, adolescence Pneumococcal 15-valent conjugate vaccine (PCV15; Vaxneuvance) or pneumococcal 20-valent conjugate vaccine (PCV20; Prevnar 20) for all children aged 2 through 59 months (less than 5 years of age) according to currently recommended PCV dosing and schedules. Note: ...
Currently, a single heptavalent pneumococcal protein conjugate vaccine is licensed for use in the United States and is recommended for routine administration to all children, beginning at 2 months of age. It also is recommended for children between 24 and 59 months of age who are at high risk...
In a multi-centre, double-blind randomised controlled trial, children received two doses, 2-months apart of the 10vPHiD-CV or quadrivalent meningococcal-ACYW135 conjugate vaccine. Active surveillance for acute exacerbations, respiratory symptoms and antibiotic use was undertaken through to 12-months ...
A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 months (42-89 days) and 2 to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Si...